Evidence map›Paper›PMID 40428399›Full record

ArticleGenes2025

PAX3 Regulatory Signatures and Gene Targets in Melanoma Cells.

Stephen P G Moore, Shripushkar Ganesh Krishnan, Rutu Jaswanth Kothari, Noah B Prince, Colin Kenny, Chao Zhang, Deborah Lang

Abstract read
In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Genetic architecture of craniofacial morphogenesis: roles ofFrontiers in cell and developmental biology · 2026
    Review
  3. A novel frameshift variant ofFrontiers in genetics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Stephen P G MooreDepartment of Dermatology, Boston University, Boston, MA 02118, USA.ORCID 0000-0002-3311-4472
Shripushkar Ganesh KrishnanDepartment of Dermatology, Boston University, Boston, MA 02118, USA.ORCID 0009-0008-0019-9589
Rutu Jaswanth KothariDepartment of Dermatology, Boston University, Boston, MA 02118, USA.
Noah B PrinceDepartment of Dermatology, Boston University, Boston, MA 02118, USA.
Colin KennyDepartment of Surgery, University of Iowa, Iowa City, IA 52242, USA.
Chao ZhangDepartment of Medicine, Boston University, Boston, MA 02118, USA.ORCID 0000-0001-8019-7998
Deborah LangDepartment of Dermatology, Boston University, Boston, MA 02118, USA.ORCID 0000-0003-1057-0923

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
NRSA Training CoreTL1TR001410 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOTTON, DARRELL N. · 2015 to 2024
$4.3M
The shared and distinct cistromes of YAP and TAZ in melanomaR03CA288281 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Deborah Lang · 2025 to 2026
$164k
Boston University Genome Science Institute (GSI) pilot project program N/ALeo Foundation LF-OC-21-00088NCATS NIH HHS TL1 TR001410NCATS NIH HHS UL1 TR001430NCI NIH HHS R03 CA288281NIH HHS 1R03CA288281-01A1NIH HHS 1TL1TR001410-01A1NIH HHS 1UL1TR001430-01A1The American Cancer Foundation DBG-23-1152683-01-RMCThe American Cancer Foundation IRG-22-153-42-IRG-07The American Cancer Foundation TLC-24-1345883-01-TLC
6 · The paper itself

Abstract

BACKGROUND/

objectivesPAX3 is a transcription factor that drives melanoma progression by promoting cell growth, migration, and survival, while inhibiting cellular terminal differentiation. However, known PAX3 target genes are limited and cannot fully explain the wide impact of PAX3 function. The PAX3 protein can regulate DNA through two separate binding domains, the Paired Domain (PD) and Homeodomain (HD), which bind different DNA motifs. It is not clear if these two domains bind and work together to regulate genes and if they promote all or only a subset of downstream cellular events.

methodsPAX3 direct downstream targets were identified using Cleavage Under Targets & Release Using Nuclease (CUT&RUN) assays in SK-MEL-5 melanoma cells. PAX3-binding genomic regions were identified through MACS2 peak calling, and peaks were categorized based on the presence of PD and/or HD binding sites (or neither) through HOMER motif analysis. The peaks were further characterized as Active, Primed, Poised, Repressed, or Closed based on ATAC-seq data and CUT&RUN for histone Post-Translational Modifications H3K4me1, H3K4me3, H3K27me3, and H3K27Ac.

resultsThis analysis revealed that most of the PAX3 binding sites in the SK-MEL-5 cell line were primarily through the PD and connected to Active genes. Surprisingly, PAX3 does not commonly act as a repressor in SK-MEL-5 cells. Pathway analysis identified genes involved with transcription, RNA modification, and cell growth. Peaks located in distal enhancer elements were connected to genes involved in neuronal growth, function, and signaling.

conclusionsOur results reveal novel PAX3 regulatory regions and putative genes in a melanoma cell line, with a predominance of PAX3 PD binding on active sites.

Indexed as

Gene Expression Regulation, NeoplasticMelanomaPAX3 Transcription FactorBinding SitesCell Line, TumorHistonesHumansHistonesPAX3 protein, humanPAX3 Transcription Factorgene regulationmelanomaPAX3PAX proteinstranscription factortranscriptomics

Identifiers

PMID40428399
PMCPMC12111051

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.